DOW JONES25,409.36-357.28 -1.39%
S&P 5002,954.22-24.54 -0.82%
NASDAQ8,567.37+0.89 0.01%

BMO Capital Initiates Coverage On Mirati Therapeutics with Market Perform Rating, Announces $101 Price Target

BMO Capital analyst George Farmer initiates coverage on Mirati Therapeutics (NASDAQ:MRTX) with a Market Perform rating and a $101 price target.

Benzinga · 01/28/2020 11:51

BMO Capital analyst George Farmer initiates coverage on Mirati Therapeutics (NASDAQ:MRTX) with a Market Perform rating and a $101 price target.